A Study of MEDI9197 in Subjects With Solid Tumors or CTCL and in Combination With Durvalumab and/or Palliative Radiation in Subjects With Solid Tumors

NCT02556463 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

53

Enrollment

INDUSTRY

Sponsor class

Stopped Company strategy

Conditions

Solid Tumors
CTCL
Cancer

Interventions

DRUG: MEDI9197
BIOLOGICAL: durvalumab

Sponsor

MedImmune LLC